Faron Pharmaceuticals Oy (FPHAF) Research

Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical firm dedicated to drug discovery and development. The company is advancing a pipeline of proprietary drug candidates that harness immune modulation to address significant unmet medical needs, spanning immuno-oncology, organ protection, and regenerative medicine. Its principal product candidates include Traumakine, an intravenous interferon beta-1a therapy, which targets acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant procedures, and ischemia-reperfusion injury. Additionally, Bexmarilimab stands as a significant candidate, representing a novel precision immunotherapy for various cancers, such as solid tumors, non-small cell lung carcinoma, and hematological malignancies. Faron also has Haematokine in development, a new chemical entity and AOC3 inhibitor designed to treat hematological malignancies and bone marrow conditions. Established in 2003, Faron Pharmaceuticals Oy maintains its headquarters in Turku, Finland.

Open Faron Pharmaceuticals Oy (FPHAF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.